- In October 2023, Labcorp launched a tri-biomarkers blood test aimed at improving the diagnosis of Alzheimer’s disease by detecting multiple biomarkers simultaneously. This advancement could enable earlier and more accurate diagnosis, supporting better treatment planning and patient care
- In October 2023, Mindray introduced high-sensitivity NT-proBNP and troponin I (hs-cTnI) cardiac biomarkers to its product lineup. These tests enhance the detection and management of cardiovascular diseases by providing more precise and timely diagnostic information
- In August 2023, Quest Diagnostics partnered with Envision Sciences to commercialize a novel prostate cancer biomarker test. This test helps identify severe and aggressive forms of prostate cancer, aiding clinicians in making more informed treatment decisions
- In February 2023, Cardio Diagnostics Holdings Inc. launched PrecisionCHD, an epigenetic-genetic blood test designed for early diagnosis of coronary heart disease. The test offers the potential for proactive disease management through early detection and risk stratification
- In August, 2022: Thermo Fisher Scientific, Inc. launched CE-IVD (IVDD) NGS test and analysis software to expand access to personalized oncology biomarker testing. This announcement underscores the company's commitment to advancing the accessibility and accuracy of molecular diagnostics for cancer patients. The CE-IVD certification is a crucial regulatory milestone, indicating that the NGS test and associated software meet the rigorous standards required for diagnostic use in Europe. This certification ensures the reliability and consistency of the test results, making them suitable for clinical decision-making
Frequently Asked Questions
One prominent trend in the global biomarker technologies market is the increasing integration of artificial intelligence and popular voice-controlled ecosystems. This fusion significantly enhances user convenience and provides more intuitive control over security systems.
The extensively used in early-stage drug discovery to identify and validate therapeutic targets, such as BRCA1/2 gene mutations in breast cancer, helping pharmaceutical companies such as AstraZeneca develop targeted drugs such as Olaparib is a major driver contributing to the growing demand for biomarker technologies across residential, commercial, and institutional sectors.
The biomarker validation requires establishing analytical and clinical validity, involving rigorous testing across diverse populations is the major challenges in the biomarker technologies market.
The consumables segment is anticipated to dominate the largest market revenue share of 49.14% in 2025, owing to the high repeat purchase rate, increasing demand in routine testing, and the growing volume of biomarker-based assays across diagnostics and research labs.
